Effects of Bubble-PEP After Open Heart Surgery on Blood Gases, Dyspnea, Secretion Status, and Pain (BUBBLE-PEP)
The Effect of Bubble-PEP Intervention After Open Heart Surgery on Arterial Blood Gas, Dyspnea, Secretion Status, and Pain: A Randomized Controlled Study
This randomized controlled study aims to evaluate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on arterial blood gas parameters, dyspnea, respiratory secretion status, and pain in patients undergoing open-heart surgery.
The study will be conducted in the Cardiovascular Surgery Department and Intensive Care Unit of Afyonkarahisar Health Sciences University Health Research and Application Center, Türkiye. A total of 92 adult patients undergoing coronary artery bypass grafting or heart valve surgery will be included. Participants will be randomly assigned to an intervention group (n=46) or a control group (n=46) using stratified block randomization based on surgical procedure.
Both groups will receive standard postoperative care, including breathing exercises, chest percussion, and incentive spirometry. In addition to standard care, the intervention group will receive Bubble-PEP therapy twice daily for three consecutive days following extubation. Each session will consist of three sets of 10 expirations.
Arterial blood gas parameters, dyspnea, respiratory secretion status, and pain will be assessed at baseline, during follow-up, and after completion of the intervention. Patient satisfaction will also be evaluated.
The study aims to determine whether adding Bubble-PEP therapy to standard postoperative care improves respiratory outcomes and contributes to evidence-based nursing care following open-heart surgery.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Design and Setting This study is designed as a randomized controlled trial to investigate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on arterial blood gas parameters, dyspnea, respiratory secretion status, and pain following open-heart surgery.
The study will be conducted in the Cardiovascular Surgery Department and Intensive Care Unit of Afyonkarahisar Health Sciences University Health Research and Application Center, Türkiye. Ethical approval was obtained from the Non-Interventional Scientific Research Ethics Committee of Afyonkarahisar Health Sciences University on October 2, 2026 (Decision No. 740).
Participants and Sample Size The study will include 92 adult patients undergoing coronary artery bypass grafting (CABG) or heart valve surgery, with 46 patients assigned to each group.
The sample size was calculated using G*Power 3.1.9.7, based on an effect size of 0.659 for PaO2, a significance level of 0.05, and 80% statistical power. The initial sample size was 76 participants, which was increased to 92 to account for an anticipated 20% dropout rate.
Eligible participants will be aged 18 years or older, have undergone CABG or heart valve surgery, be extubated and hemodynamically stable, be able to communicate in Turkish, and provide informed consent.
Randomization and Blinding Participants will be allocated to intervention and control groups in a 1:1 ratio using stratified block randomization according to surgical type (CABG or heart valve surgery).
Computer-generated randomization lists will be prepared by an independent researcher who is not involved in intervention delivery or outcome assessment. Group allocation will be implemented using sequentially numbered, sealed envelopes.
Due to the nature of the intervention, participants and the researcher administering Bubble-PEP therapy cannot be blinded. However, outcome assessments will be conducted by an independent assessor blinded to group allocation. The statistician will also remain blinded to group identity until completion of the analysis.
Control Group Participants in the control group will receive standard postoperative care, including breathing exercises, chest percussion, and incentive spirometry.
Intervention Group Participants in the intervention group will receive Bubble-PEP therapy in addition to standard postoperative care.
The Bubble-PEP apparatus will consist of a 1.5-liter plastic bottle filled with water to a depth of 10 cm and a tube approximately 80 cm long with an internal diameter of 8 mm. A separate bottle and tube will be provided for each participant.
Bubble-PEP therapy will begin after extubation, once the patient is conscious, hemodynamically stable, and considered clinically suitable by the treating physician.
During the intervention, patients will be placed in an upright sitting position and instructed to inhale deeply through the nose and then exhale slowly, continuously, and in a controlled manner through the tube submerged in water.
The intervention will be administered twice daily, in the morning and afternoon, on the first, second, and third days after extubation. Each session will consist of three sets of 10 expirations, totaling 30 expirations per session.
Outcome Measurements
The primary outcome measures will include:
Arterial blood gas parameters: PaO2, PaCO2, pH, HCO3-, base excess (BE), and oxygen saturation (SpO2).
Dyspnea severity assessed using the Modified Borg Dyspnea Scale. Respiratory secretion status and cough effectiveness assessed using a researcher-developed postoperative respiratory secretion and cough effectiveness assessment form.
Secondary outcome measures will include:
Pain intensity assessed using the Visual Analog Scale (VAS). Patient satisfaction assessed using a visual patient satisfaction scale.
Data Collection and Assessment Schedule Preoperative demographic and clinical data will be collected after obtaining written informed consent. Preoperative dyspnea and pain assessments will also be performed.
The first calendar day following extubation will be designated as Day 1 (G1). Baseline postoperative assessments will be performed on Day 1, before the first Bubble-PEP session, preferably between 09:00 and 10:00, provided that at least six hours have elapsed since extubation and the patient is hemodynamically stable.
Follow-up assessments will be performed on Days 2 and 3 (G2 and G3), between 09:00 and 10:00, before the daily intervention.
The final assessment will be performed on Day 4 (G4), between 09:00 and 10:00, following completion of the three-day intervention period. Patient satisfaction will also be evaluated during the final assessment.
Arterial blood gas results obtained as part of routine clinical care will be recorded from patient records.
Statistical Analysis Data will be analyzed using SPSS software. Descriptive statistics will include frequencies, percentages, means, and standard deviations.
Depending on the distribution of the data, independent-samples t-tests or Mann-Whitney U tests will be used for between-group comparisons. Paired t-tests or Wilcoxon signed-rank tests will be used for within-group comparisons.
Repeated-measures analysis of variance or Friedman tests will be used to evaluate changes over time, as appropriate. Exploratory subgroup analyses based on surgical type may be performed if the sample size is sufficient.
Statistical significance will be set at p < 0.05.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Hamide N Erkan, Research Assistant
- Phone Number: 05418573326
- Email: hamidenurerkan@gmail.com
Study Locations
-
-
Centre
-
Afyonkarahisar, Centre, Turkey (Türkiye), 03100
- Afyonkarahisar University of Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Having undergone Coronary Artery Bypass Graft (CABG) or heart valve surgery,
- Being 18 years of age or older,
- Not having undergone postoperative revision surgery,
- Having no neurological or severe cognitive impairment, and no postoperative delirium,
- Being extubated and hemodynamically stable,
- Being able to communicate in Turkish,
- Being willing to participate in the research.
Exclusion Criteria:
- Having undergone a surgical procedure other than CABG or heart valve surgery,
- Patients who require revision surgery during the postoperative period,
- Patients with neurological or severe cognitive impairment,
- Patients experiencing postoperative delirium,
- Individuals aged 18 years or younger,
- Patients who have not been extubated,
- Patients who are hemodynamically unstable,
- Individuals with whom it is not possible to communicate in Turkish, or those who are unwilling to participate in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Bubble-PEP Intervention Group
Patients in the intervention group will receive Bubble Positive Expiratory Pressure (Bubble-PEP) therapy in addition to routine postoperative care following open-heart surgery. I will evaluate the intervention's effects on arterial blood gas parameters, dyspnea, secretion status, and pain. |
A researcher-prepared Bubble Positive Expiratory Pressure (Bubble-PEP) device will be used in addition to standard postoperative care. The device will consist of a 1.5-liter plastic bottle filled with water to a depth of 10 cm and an approximately 80-cm-long tube with an internal diameter of 8 mm. Each patient will be provided with an individual bottle and tube. Bubble-PEP therapy will be initiated after extubation when the patient is conscious, hemodynamically stable, and considered clinically suitable by the treating physician. During the intervention, the patient will be placed in an upright sitting position and instructed to inhale deeply through the nose, followed by slow, controlled, and continuous exhalation through the tube submerged in water. The intervention will be administered twice daily, in the morning and afternoon, on the first, second, and third days after extubation. Each session will consist of three sets of 10 expirations, totaling 30 expirations per session.
Other Names:
|
|
No Intervention: Control Group
Patients in the control group will receive routine postoperative care following open-heart surgery, with no additional interventions applied. I will assess arterial blood gas parameters, dyspnea, secretion status, and pain. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Arterial Oxygen Partial Pressure(PaO₂)
Time Frame: Days 1, 2, and 3 post-extubation
|
Arterial oxygen partial pressure(PaO₂) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in PaO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group. |
Days 1, 2, and 3 post-extubation
|
|
Change in Arterial Carbon Dioxide Partial Pressure(PaCO₂)
Time Frame: Days 1, 2, and 3 post-extubation
|
Arterial carbon dioxide partial pressure (PaCO₂) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in PaCO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group. |
Days 1, 2, and 3 post-extubation
|
|
Change in Arterial Blood pH
Time Frame: Days 1, 2, and 3 post-extubation
|
Arterial blood pH will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in arterial blood pH will be evaluated and compared between the Bubble-PEP intervention group and the control group. |
Days 1, 2, and 3 post-extubation
|
|
Change in Arterial Oxygen Saturation (SaO₂)
Time Frame: Days 1, 2, and 3 post-extubation
|
Arterial oxygen saturation (SaO₂, %) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in SaO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group. |
Days 1, 2, and 3 post-extubation
|
|
Change in Arterial Bicarbonate Level (HCO₃-)
Time Frame: Days 1, 2, and 3 post-extubation
|
Arterial bicarbonate levels (HCO₃-, mmol/L) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in HCO₃- levels will be evaluated and compared between the Bubble-PEP intervention group and the control group. |
Days 1, 2, and 3 post-extubation
|
|
Change in Arterial Blood Base Excess (BE)
Time Frame: Days 1, 2, and 3 post-extubation
|
Arterial blood base excess (BE, mmol/L) will be assessed using arterial blood samples obtained from patients following open-heart surgery. Changes in BE levels will be evaluated and compared between the Bubble-PEP intervention group and the control group. |
Days 1, 2, and 3 post-extubation
|
|
Change in Dyspnea Severity
Time Frame: Days 1, 2, and 3 post-extubation
|
Dyspnea severity will be assessed in patients following open heart surgery using a standardized dyspnea assessment scale. Changes in dyspnea scores will be evaluated and compared between the Bubble-PEP intervention group and the control group. Higher scores will indicate greater dyspnea severity. |
Days 1, 2, and 3 post-extubation
|
|
Change in Respiratory Secretion Status
Time Frame: Days 1, 2, and 3 post-extubation
|
Respiratory secretion status will be assessed in patients following open heart surgery to evaluate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on airway secretion clearance. Changes in secretion status will be evaluated and compared between the intervention and control groups. |
Days 1, 2, and 3 post-extubation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Postoperative Pain Intensity
Time Frame: Days 1, 2, and 3 post-extubation
|
Postoperative pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes in pain scores will be compared between the Bubble-PEP intervention group and the control group. |
Days 1, 2, and 3 post-extubation
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Santos MD, Milross MA, McKenzie DK, Alison JA. Bubble-positive expiratory pressure device and sputum clearance in bronchiectasis: A randomised cross-over study. Physiother Res Int. 2020 Jul;25(3):e1836. doi: 10.1002/pri.1836. Epub 2020 Feb 29.
- Pieczkoski SM, de Oliveira AL, Haeffner MP, Azambuja ACM, Sbruzzi G. Positive expiratory pressure in postoperative cardiac patients in intensive care: A randomized controlled trial. Clin Rehabil. 2021 May;35(5):681-691. doi: 10.1177/0269215520972701. Epub 2020 Nov 24.
- OMNIA, M. N., FATMA, S., GHADA, A. A., & ISMAIL, M. (2024). Efficacy of Bubble Positive Expiratory Pressure Device in Post Thoracic Surgery Patients. The Medical Journal of Cairo University, 92(03), 119-127.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BUBBLEPEP-2026-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data will not be made publicly available or shared with other researchers. The study involves patients undergoing open-heart surgery, and participant confidentiality and data privacy will be maintained in accordance with the approved research protocol and applicable ethical and data protection requirements.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.